News and Announcements
SUDA Receives Positive Response From FDA Regarding SUD-001 Development Plan
- Published August 06, 2015 11:55AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
6th August 2015, Perth Australia, ASX Announcement
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that it has received a written response from the US FDA regarding the development plan for the Company’s SUD-001 sumatriptan oral spray for the treatment of migraine.
SUDA submitted a Type C meeting briefing package to the FDA on 13 June 2015 containing details of the proposed pivotal study of SUD-001 and other activities intended to support a New Drug Application in the USA. SUDA’s FDA briefing package was accompanied by a series of questions relating to the development plan.
The FDA acknowledged SUDA’s proposed development strategy and requested only minor justifications to the study design. Furthermore, the agency had no comments regarding SUDA’s plans for chemistry, manufacturing, controls and non-clinical studies of SUD-001. The FDA also requested that SUDA submit a paediatric study plan in migraineurs aged 6-17 years who could benefit from SUDA’s first-in-class oral-spray migraine therapy.
SUDA designed the proposed pivotal trial of SUD-001 with its Clinical Advisory Board, US regulatory agents and experts in pharmacokinetic (PK) studies. The development strategy is intended to accelerate registration of SUD-001 by utilising a PK approach thus not requiring clinical efficacy studies in migraine patients. Instead, SUDA’s two-part pivotal study will assess the PK parameters of SUD-001 (eg: the plasma concentration of
sumatriptan) compared to the currently approved formulations of sumatriptan in approximately 70 healthy subjects.
Mr Stephen J Carter, CEO commented: “We are delighted that the FDA has broadly accepted our development plan, which is designed to support the submission of a New Drug Application in the USA by the end of 2017. Under this plan, we expect to save significant time and capital by avoiding the need to conduct costly efficacy studies prior to registration of SUD-001 in the USA. The FDA’s constructive responses keep us on track to commence our pivotal PK study of SUD-001 in early CY2016 and, importantly, will strengthen our negotiating position with prospective pharmaceutical partners in the USA, Europe and elsewhere by quantifying the cost and time to get to market.”
To read the full announcement, please click here.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
